🔴 GRAIL is trading 10.17% down in pre-market after Q3 revenue missed analyst expectations

GRAIL is trading at $129.05, down 10.17% before the November 5, 2026, market open, after Q3 revenue missed analyst expectations.

• November 4 results showed Q3 revenue of $37.5 million, below expectations, despite Galleri test volume rising about 24%.
• Net loss widened 16% year over year to $103.6 million, while adjusted EBITDA loss increased 29%.
• After-hours reporting linked the sharp decline to the revenue miss; biotech’s positive pre-market trend does not explain the drop.